SmartPharm’s gene-encoded therapeutics (GET) approach has multiple benefits compared to traditional viral-vectored gene therapy:
SmartPharm Therapeutics has been awarded a contract from the Defense Advanced Research Projects Agency (DARPA) to rapidly develop a DNA-based neutralizing antibody that can be given to people as an intramuscular injection to block infection by COVID-19.